1- Magliano DJ, Boyko EJ; IDF Diabetes Atlas 10th edition scientific committee. IDF DIABETES ATLAS [Internet]. 10th ed. Brussels: International Diabetes Federation; 2021.
2- Parker ED, Lin J, Mahoney T, Ume N, Yang G, Gabbay RA et al. Economic costs of diabetes in the US in 2022. Diabetes Care. 2024; 47(1):26-43.
3- Adler AI, Coleman RL, Leal J, Whiteley WN, Clarke P, Holman RR. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). The Lancet. 2024; S0140-6736(24)00537-3.
4- dos Reis RCP, Duncan BB, Szwarcwald CL, Malta DC, Schmidt MI. Control of Glucose, Blood Pressure, and Cholesterol among Adults with Diabetes: The Brazilian National Health Survey. J Clin Med. 2021; 10(15):3428.
5- Samson SL, Vellanki P, Blonde L, Christofides EA, Galindo RJ, Hirsch IB et al. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update. Endocr Pract. 2023; 29(5):305-340.
6- Lyra R, Albuquerque L, Cavalcanti S, Tambascia M, Valente F, Bertoluci M. Tratamento farmacológico da hiperglicemia no DM2. Diretriz Oficial da Sociedade Brasileira de Diabetes (2023).
7- American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. Diabetes Care. 2024; 47(Suppl 1):S158-S178. Erratum in: Diabetes Care. 2024 May 02.
8- Bertoluci MC, Silva Júnior WS,Valente F, Araujo LR, Lyra R, de Castro JJ, et al. 2023; UPDATE: Luso-Brazilian evidencebased guideline for the management of antidiabetic therapy in type 2 diabetes. Diabetol Metab Syndr. 2023 Jul 19;15(1):160).
9- Wu Q, Liu M, Fang Z, Li C, Zou F, Hu L et al. Efficacy and safety of empagliflozin at different doses in patients with type 2 diabetes mellitus: A network meta‐analysis based on randomized controlled trials. J Clin Pharm Ther. 2022; 47(3):270-286.
10- McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021; 6(2):148-158.
11- Butler J, Packer M, Filippatos G, Ferreira JP, Zeller C, Schnee J et al. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J. 2022; 43(5):416-426.
12- The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117-127.
13- Moura F, Salles JEN, Valente F, Almeida-Pititto B, Fonseca RMC, Cavalcanti S. Abordagem do paciente idoso com diabetes mellitus. Diretriz Oficial da Sociedade Brasileira de Diabetes (2023).
14- Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019; 321(1):69-79.
15- Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ et al. Effect of linagliptin vs glimepiride on major cardiovascular events in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. 2019; 322(12):1155-1166.
16- Radholm K, Wu J, Karlson BW, Zhou Z, Landin-Olsson M, Svensson AM. Safety and efficacy of empagliflozin and linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2023;25(1):213-222.
Exclusividade médica
